The Art of Decentralizing Pediatric Rare Disease Studies

Logo
Presented by

Betsy Reid Senior VP, Pediatrics, Adam Bloomfield, MD, FAAP Executive Director, Medical Affairs, Rare Diseases & Pediatrics

About this talk

Topic : The Art of Decentralizing Pediatric Rare Disease Studies: Clinical Trials Suited for Daily Life Pediatric rare disease trials combine rarity of disease with a restricted and geographically-dispersed population of vulnerable subjects for research, creating unique challenges for study design and execution. Recruitment is challenging, as patients, parents and caregivers need to juggle school schedules, work responsibilities and family obligations to accommodate study participation. Incorporating decentralized clinical trial (DCT) strategies can help sponsors attract patients and increase access, enrollment and retention by limiting site visits and facilitating participation for those who might not otherwise be able — or willing — to travel to distant sites or specialized centers. Join this webinar to learn: • Challenges of conducting clinical research in pediatric rare diseases • Potential applications of DCT strategies in pediatric rare disease studies • Risks to applying DCT strategies in these clinical trials • Key considerations when operationalizing pediatric rare disease studies with decentralized elements • Future trends in decentralization for pediatric rare disease studies Please note: If we do not attend to your questions, we may follow up afterwards. Questions? Contact info@premier-research.com
Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (96)
Subscribers (4561)
Premier Research is a clinical research company, dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.